IMVT Stock Overview

A clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. More details

IMVT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 75.52% per year

Analysts in good agreement that stock price will rise by 99.2%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Significant insider selling over the past 3 months

My Notes

Capture your thoughts, links and company narrative

Immunovant, Inc. Competitors

RayzeBio

NasdaqGM:RYZB

US$3.7b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Avidity Biosciences

NasdaqGM:RNA

US$3.7b

Scholar Rock Holding

NasdaqGS:SRRK

US$4.3b

Price History & Performance

Summary of share price highs, lows and changes for Immunovant
Historical stock prices
Current Share Price	US$24.49
52 Week High	US$45.58
52 Week Low	US$23.91
Beta	0.63
1 Month Change	-14.76%
3 Month Change	-12.60%
1 Year Change	-41.87%
3 Year Change	187.44%
5 Year Change	56.79%
Change since IPO	146.13%

Recent updates

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 27

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Jul 18

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

Jun 27

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Apr 19

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Apr 04

Immunovant: An Intriguing And Developing Story

Jan 25

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Shareholder Returns

	IMVT	US Biotechs	US Market
7D	-5.3%	0.7%	0.6%
1Y	-41.9%	-3.4%	23.8%

Return vs Industry: IMVT underperformed the US Biotechs industry which returned -3.3% over the past year.

Return vs Market: IMVT underperformed the US Market which returned 24.6% over the past year.

Price Volatility

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.0%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IMVT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IMVT's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	207	Pete Salzmann	immunovant.com

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York.

Immunovant, Inc. Fundamentals Summary

How do Immunovant's earnings and revenue compare to its market cap?
IMVT fundamental statistics
Market cap	US$3.78b
Earnings (TTM)	-US$323.01m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-11.1x

P/E Ratio

Is IMVT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMVT income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$323.01m
Earnings	-US$323.01m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.20
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IMVT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 05:02
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunovant, Inc. is covered by 17 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Jason Matthew Gerberry	BofA Global Research
Louise Chen	Cantor Fitzgerald & Co.

IMVT Stock Overview

Rewards

Risk Analysis

Immunovant, Inc. Competitors

NasdaqGM:RYZB

US$3.7b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:RNA

US$3.7b

NasdaqGS:SRRK

US$4.3b

Price History & Performance

Recent News & Updates

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

Recent updates

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease